Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias
We investigated a large number of acute myeloid leukemia (AML) samples (n=959) for the presence of the JAK2 V617F mutation. We found a low incidence of the mutation in these AML samples (1%). JAK2 V617F mutations clustered in AML samples with an aberrant karyotype (p
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2007-01-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/4295 |